Drug intelligence / Profile preview

siREV3L

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

siREV3L is a small interfering RNA (siRNA) designed to silence the expression of the *REV3L* gene, which encodes the catalytic subunit of DNA polymerase zeta (Pol ζ). Pol ζ is a specialized B-family DNA polymerase that plays a critical role in translesion synthesis (TLS), a DNA damage tolerance mechanism that allows cells to replicate past bulky DNA lesions, such as those induced by ultraviolet light or platinum-based chemotherapeutics. By depleting REV3L, siREV3L inhibits the TLS pathway, thereby increasing the accumulation of DNA double-strand breaks and sensitizing cancer cells to DNA-damaging treatments. This approach is primarily investigated in preclinical research as a combination therapy to overcome chemoresistance in various malignancies, including prostate, breast, cervical, and ovarian cancers.

Other names
REV3L siRNAREV-3L siRNAREV 3L siRNAsiRNA-REV3LsiRNA-REV-3LsiRNA-REV 3LREV3L-specific siRNAREV-3L-specific siRNAREV 3L-specific siRNA
02

Targets

DNA polymerase familyREV3L (DNA polymerase zeta catalytic subunit)

Beyond the preview

Go deeper on siREV3L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siREV3L.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call